Researchers use targeted lipid nanoparticles loaded with mRNA to reprogram T cells to fight autoimmune diseases ...

In vivo CAR T cell generation is a pioneering immunotherapy approach that reprograms the immune system to fight cancer and ...

Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without ...

A new approach induces the patient’s body to produce its own CAR-T cells, relying on the same messenger RNA (mRNA) technology ...

Treating types of cancer with CAR T-cell therapy is expensive and inconvenient, but a streamlined approach that creates the ...

Researchers present a new method to safely and preferentially generate CAR T cells directly inside the body using targeted lipid nanoparticles that deliver mRNA directly to T cells. The approach ...

Instead of extracting T-cells and engineering them in a lab, researchers have delivered mRNA directly into circulating immune ...

– MT-302 and MT-303 embody the first clinical applications of in vivo mRNA CAR therapies administered systemically – – Initial translational results support proof-of-mechanism with immune ...

At the 11th Congress European Academy of Neurology, which was held in Helsinki June 21 to June 24, researchers presented new ...

– MT-302 and MT-303 embody the first clinical applications of in vivo mRNA CAR therapies administered systemically – – Initial translational results support proof-of-mechanism with immune ...

– MT-302 and MT-303 embody the first clinical applications of in vivo mRNA CAR therapies administered systemically – – Initial translational results support proof-of-mechanism with immune ...

MT-302: TROP2-Targeted mRNA CAR Therapy in Advanced Epithelial Tumors. MT-302 is the first intravenously delivered mRNA-based CAR therapy to enter clinical trials.